New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
06:21 EDTREGNRegeneron shares attractive at current levels, says Citigroup
Citigroup expects sales of Eylea to rebound in Q2 and it finds shares of Regeneron attractive at current levels. Citi says the stock has been weak over the past two weeks amid concerns that use of Avastin will grow. After surveying 31 retinal specialists, Citi keeps a Buy rating on Regeneron with a $390 price target.
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
07:31 EDTREGNRegeneron's EYLEA Injection granted designation for treatment of retinopathy
Subscribe for More Information
September 8, 2014
07:15 EDTREGNIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use